Clevidipine

Results: 65



#Item
41Krystexxa (pegloticase) injection label

Krystexxa (pegloticase) injection label

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2012-04-17 11:20:42
42HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NAGLAZYME® safely and effectively. See full prescribing information for NAGLAZYME.  

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NAGLAZYME® safely and effectively. See full prescribing information for NAGLAZYME. 

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2013-04-01 15:24:13
43HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Remodulin safely and effectively. See full prescribing information for Remodulin. REMODULIN® (treprostinil) Injecti

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Remodulin safely and effectively. See full prescribing information for Remodulin. REMODULIN® (treprostinil) Injecti

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2013-09-27 15:15:14
44•  HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Voluven® safely and effectively. See full prescribing information for Voluven®.

• HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Voluven® safely and effectively. See full prescribing information for Voluven®.

Add to Reading List

Source URL: www.fda.gov

Language: English
45CDER New Molecular Entity (NME) Drug and New Biologic Approvals for Calendar Year 2008 Updated through December 31, 2008 NME New Drug Application (NDA) Approvals: Application Type

CDER New Molecular Entity (NME) Drug and New Biologic Approvals for Calendar Year 2008 Updated through December 31, 2008 NME New Drug Application (NDA) Approvals: Application Type

Add to Reading List

Source URL: www.fda.gov

Language: English
46C:�uments and Settings�KOWSKY.FDA�Documents�d Processing Documents�gs�� inhibitors and ARBS�asartan PEds�PAC summary[removed]doc

C:uments and SettingsKOWSKY.FDADocumentsd Processing Documentsgs inhibitors and ARBSasartan PEdsPAC summary[removed]doc

Add to Reading List

Source URL: www.fda.gov

Language: English - Date: 2006-03-14 13:56:21
47HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ICLUSIG safely and effectively. See full prescribing information for ICLUSIG. ICLUSIG® (ponatinib) tablets for oral

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ICLUSIG safely and effectively. See full prescribing information for ICLUSIG. ICLUSIG® (ponatinib) tablets for oral

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2013-12-23 15:37:55
48HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Cleviprex safely and effectively. See full prescribing information for Cleviprex. Cleviprex (clevidipine)injectablee

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Cleviprex safely and effectively. See full prescribing information for Cleviprex. Cleviprex (clevidipine)injectablee

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2011-12-13 16:12:35
49Krystexxa (pegloticase) injection label

Krystexxa (pegloticase) injection label

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2012-04-17 11:28:17
50

PDF Document

Add to Reading List

Source URL: www.fda.gov

Language: English